1. In Vivo
  2. >>Deal-Making

Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2019

A Look At Financing, M&A And Alliance Activity October-December 2019

 
• By Amanda Micklus and Maureen Riordan

Device financing during 2019’s final quarter totaled $1.6bn, a substantial decrease from Q3’s $4.05bn. Merger and acquisition activity, almost doubled from the previous quarter reaching $6.1bn; Stryker’s 4.7bn takeover of Wright Medical was the only billion-dollar transaction. Financings by diagnostics/research players totaled $1.3bn (the lowest quarter of the year) and eight companies were acquired, five of which together were valued at $981m.

Device companies finished 2019 with $1.6bn, a substantial 60% decrease compared with the $4.05bn raised during Q3. Some financings types experienced increases, such as early-stage venture rounds and FOPOs, but debt offerings and IPOs were considerably down versus the last quarter. (See Exhibit 1.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

Deals Shaping The Industry, March 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By Jo Shorthouse

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.